Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction

E-ISSN： 1996-3181|10|8|892-898

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.10, Iss.8, 2011-12, pp. : 892-898

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Could Sigma Receptor Ligands be a Treatment for Methamphetamine Addiction?

Current Drug Abuse Reviews, Vol. 3, Iss. 3, 2010-09 ,pp. : 156-162

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Multiple Sclerosis

Current Medicinal Chemistry, Vol. 16, Iss. 36, 2009-12 ,pp. : 4858-4868

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4498-4507

Bentham Science Publishers

Access to resources Recommend Favorite

Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

By Cao Yanguang Balthasar Joseph Jusko William

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 5, 2013-10 ,pp. : 597-607

Springer Publishing Company

Access to resources Recommend Favorite

Population Pharmacokinetic/Pharmacodynamic Analyses as the Basis for Dosing of Therapeutic Monoclonal Antibodies

By Meibohm Bernd

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 823-824

Adis International

Access to resources Recommend Favorite